RU2470936C2 - Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения - Google Patents

Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения Download PDF

Info

Publication number
RU2470936C2
RU2470936C2 RU2009125916/04A RU2009125916A RU2470936C2 RU 2470936 C2 RU2470936 C2 RU 2470936C2 RU 2009125916/04 A RU2009125916/04 A RU 2009125916/04A RU 2009125916 A RU2009125916 A RU 2009125916A RU 2470936 C2 RU2470936 C2 RU 2470936C2
Authority
RU
Russia
Prior art keywords
pyrimidin
morpholinothieno
methyl
aminopyrimidin
amine
Prior art date
Application number
RU2009125916/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2009125916A (ru
Inventor
Жоржетт КАСТАНЕДО
Дженнафер ДОТСОН
Ричард ГОЛДСМИТ
Дженет ГАНЗНЕР
Тим ХЕФФРОН
Симон МАТЬЕ
Алан ОЛИВЕРО
Стивен СТЭЙБЕН
Даниел П. САТЕРЛИН
Вики ЦЗУИ
Шумэй Ван
Бин-Янь ЧЖУ
Трейси БЕЙЛИСС
Ирина ЧУКАУРИ
Адриан ФОУЛКС
Нань Чи ВАНЬ
Original Assignee
Дженентек, Инк.
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39403189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2470936(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дженентек, Инк., Ф. Хоффманн-Ля Рош Аг filed Critical Дженентек, Инк.
Publication of RU2009125916A publication Critical patent/RU2009125916A/ru
Application granted granted Critical
Publication of RU2470936C2 publication Critical patent/RU2470936C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
RU2009125916/04A 2006-12-07 2007-12-05 Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения RU2470936C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87342206P 2006-12-07 2006-12-07
US60/873,422 2006-12-07
PCT/US2007/086533 WO2008073785A2 (en) 2006-12-07 2007-12-05 Phosphoinositide 3-kinase inhibitor compounds and methods of use

Publications (2)

Publication Number Publication Date
RU2009125916A RU2009125916A (ru) 2011-01-20
RU2470936C2 true RU2470936C2 (ru) 2012-12-27

Family

ID=39403189

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009125916/04A RU2470936C2 (ru) 2006-12-07 2007-12-05 Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения

Country Status (19)

Country Link
US (1) US9487533B2 (https=)
EP (1) EP2114950B1 (https=)
JP (1) JP5500990B2 (https=)
KR (1) KR101507182B1 (https=)
CN (1) CN101675053B (https=)
AR (1) AR064154A1 (https=)
AU (1) AU2007333243B2 (https=)
BR (1) BRPI0717907A2 (https=)
CA (1) CA2671845C (https=)
CL (1) CL2007003523A1 (https=)
ES (1) ES2571028T3 (https=)
IL (1) IL199151A (https=)
MX (1) MX2009005925A (https=)
NO (1) NO342697B1 (https=)
PE (1) PE20081353A1 (https=)
RU (1) RU2470936C2 (https=)
TW (1) TW200829594A (https=)
WO (1) WO2008073785A2 (https=)
ZA (1) ZA200904531B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029601B1 (ru) * 2013-12-23 2018-04-30 Ле Лаборатуар Сервье Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1693804B1 (en) * 1996-09-04 2009-11-11 Intertrust Technologies Corp. Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing and rights management
WO2008070740A1 (en) * 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
US7893060B2 (en) * 2007-06-12 2011-02-22 F. Hoffmann-La Roche Ag Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
AU2008298948B2 (en) * 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042607A1 (en) * 2007-09-24 2009-04-02 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
AR073354A1 (es) * 2008-07-31 2010-11-03 Genentech Inc Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer.
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
WO2010042998A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
NZ592748A (en) 2008-10-17 2013-01-25 Akaal Pharma Pty Ltd 2-Amino-(oxadiazol-3-yl)-benzofuran derivatives and their use as S1P receptor modulators
AU2010203512C1 (en) 2009-01-08 2013-10-17 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CN102369011A (zh) 2009-03-12 2012-03-07 健泰科生物技术公司 用于治疗造血恶性肿瘤的磷酸肌醇3-激酶抑制剂化合物与化学治疗剂的组合
ES2665277T3 (es) * 2009-03-13 2018-04-25 Katholieke Universiteit Leuven K.U. Leuven R&D Análogos de purina y su uso como agentes inmunosupresores
CN102361878A (zh) 2009-03-24 2012-02-22 住友化学株式会社 用于制备硼酸酯化合物的方法
CN102459272B (zh) * 2009-05-27 2014-08-06 健泰科生物技术公司 对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法
CA2772371A1 (en) * 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
SG176959A1 (en) * 2009-06-24 2012-01-30 Genentech Inc Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
ES2558742T3 (es) 2009-09-28 2016-02-08 F. Hoffmann-La Roche Ag Compuestos inhibidores de PI3K de benzoxepina y métodos de uso
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
PH12012500901A1 (en) 2009-11-05 2016-08-05 Rhizen Pharmaceuticals Sa Novel benzopyran kinase modulators
CN102712642B (zh) * 2009-11-12 2015-08-12 霍夫曼-拉罗奇有限公司 N-7取代的嘌呤和吡唑并嘧啶化合物、组合物和使用方法
WO2011058027A2 (en) * 2009-11-12 2011-05-19 F. Hoffmann-La Roche Ag N-9-substituted purine compounds, compositions and methods of use
MX2012009059A (es) 2010-02-22 2012-09-07 Hoffmann La Roche Compuestos inhibidores de fosfoinositida 3-cinasa delta (pi3k) pirido [3,2-d]pirimidina y metodos de uso.
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations
PT2585470T (pt) * 2010-06-23 2017-03-06 Hanmi Science Co Ltd Novos derivados fundidos de pirimidina para inibição da actividade da tirosina cinase
JP5555378B2 (ja) 2010-07-14 2014-07-23 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３ｋｐ１１０デルタに選択的なプリン化合物とその使用の方法
DE102010049595A1 (de) * 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
CN103313989B (zh) 2010-12-16 2016-05-04 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
CA2825825A1 (en) * 2011-01-27 2012-08-02 The Trustees Of Princeton University Inhibitors of mtor kinase as anti-viral agents
CA2825028A1 (en) 2011-02-09 2012-08-16 F. Hoffman-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
EP2683243A4 (en) * 2011-03-09 2014-12-03 Celgene Avilomics Res Inc PI3 KINASE INHIBITORS AND USES THEREOF
WO2012126901A1 (en) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
DK3111938T3 (da) 2011-04-01 2019-07-01 Curis Inc Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe
HUE055286T2 (hu) 2011-04-08 2021-11-29 Janssen Sciences Ireland Unlimited Co Pirimidinszármazékok vírusfertõzések kezelésére
HRP20190128T1 (hr) 2011-05-04 2019-03-08 Rhizen Pharmaceuticals S.A. Novi spojevi kao modulatori protein kinaza
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
RS57851B1 (sr) 2011-11-09 2018-12-31 Janssen Sciences Ireland Uc Purinski derivati za tretman viralnih infekcija
ES2575143T3 (es) * 2011-11-23 2016-06-24 Cancer Research Technology Limited Inhibidores de tienopiridina de la proteína quinasa C atípica
CN103467482B (zh) 2012-04-10 2017-05-10 上海璎黎药业有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
JP6301316B2 (ja) 2012-05-23 2018-03-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 内胚葉細胞および肝実質細胞の組成物ならびにそれらの細胞を入手および使用する方法
WO2013182668A1 (en) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
CN109970742A (zh) 2012-07-04 2019-07-05 理森制药股份公司 选择性PI3Kδ抑制剂
CA2874800C (en) 2012-07-13 2021-04-06 Janssen R&D Ireland Macrocyclic purines for the treatment of viral infections
LT2906563T (lt) 2012-10-10 2018-06-11 Janssen Sciences Ireland Uc Pirolo[3,2-d]pirimidino dariniai virusinių infekcijų ir kitų ligų gydymui
EP2906566B1 (en) * 2012-10-10 2016-08-24 F. Hoffmann-La Roche AG Process for making thienopyrimidine compounds
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
EP2925729B1 (en) 2012-11-16 2017-10-18 Janssen Sciences Ireland UC Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
WO2014128189A1 (en) 2013-02-21 2014-08-28 Janssen R&D Ireland 2-aminopyrimidine derivatives for the treatment of viral infections
AU2014242954B2 (en) 2013-03-29 2018-03-15 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
SG11201509520QA (en) 2013-05-24 2015-12-30 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
BR112015032546B1 (pt) 2013-06-27 2022-05-17 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina e composição farmacêutica que os compreende para o tratamento de infecções virais e outras doenças
KR102322425B1 (ko) 2013-07-30 2021-11-05 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체
US9745321B2 (en) 2013-09-30 2017-08-29 Shanghai Yingli Pharmaceutical Co., Ltd Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
JPWO2015190316A1 (ja) * 2014-06-09 2017-04-20 住友化学株式会社 ピリジン化合物の製造方法
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
KR20160082062A (ko) 2014-12-30 2016-07-08 한미약품 주식회사 싸이옥소 퓨로피리미디논 유도체의 제조방법 및 이에 사용되는 중간체
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
HK1249866A1 (zh) 2015-06-29 2018-11-16 豪夫迈‧罗氏有限公司 用他塞利昔布进行治疗的方法
CN106467545B (zh) * 2015-08-20 2018-10-16 北大方正集团有限公司 一种噻吩并嘧啶化合物
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
CN109311880B (zh) 2016-06-29 2021-09-03 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新的四氢吡啶并嘧啶类化合物
AU2017289418B2 (en) 2016-07-01 2021-06-03 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
JP7274415B2 (ja) 2016-09-29 2023-05-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー ウイルス感染症および他の疾患を処置するためのピリミジンプロドラッグ
CN110573518A (zh) 2017-01-26 2019-12-13 尤拉·S·赞特里佐斯 被取代的双环嘧啶基化合物及其组合物和用途
CN107163061A (zh) * 2017-04-14 2017-09-15 江西科技师范大学 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
SG11202102343QA (en) 2018-09-11 2021-04-29 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN109540859B (zh) * 2018-11-27 2021-02-09 上海交通大学 一种水体中抗生素的分析和含量预测方法
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
US12319686B2 (en) 2019-01-17 2025-06-03 Hoffmann-La Roche Inc. Process for the preparation of tetrahydropyridopyrimidines
CN113087718B (zh) * 2020-01-09 2024-02-09 四川科伦博泰生物医药股份有限公司 噻吩并嘧啶酮类化合物及其医药应用
EP4161519A4 (en) * 2020-06-03 2024-07-17 Yumanity Therapeutics, Inc. PURINES AND METHODS OF USE
WO2022152229A1 (zh) * 2021-01-15 2022-07-21 深圳微芯生物科技股份有限公司 一类吗啉衍生物及其制备方法和应用
CN115991716B (zh) * 2021-10-19 2025-10-17 中国药科大学 嘧啶并环类化合物及其衍生物、制备方法、药物组合物和应用
CN116262758B (zh) * 2021-12-15 2025-02-28 上海博悦生物科技有限公司 7-甲基噻唑并[5,4-d]嘧啶类化合物、制备方法及其用途
CN114539293B (zh) * 2022-02-24 2023-09-22 广东晨康生物科技有限公司 一种噻吩并嘧啶类化合物或其药学上可接受的盐及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2050814A1 (de) * 1970-10-16 1972-04-20 Dr. Karl Thomae Gmbh, 7950 Biberach Neue Verfahren zur Herstellung von 2-(5-Nitro-2-furyl)-thieno eckige Klammer auf 3,2-d eckige Klammer zu pyrimidinen
SU419037A3 (https=) * 1970-11-26 1974-03-05 Эберхард Войтун, Герхард Онаккер, Бертольд Нарр, Ульрих Хорх , Рудольф Кадац
SU581868A3 (ru) * 1973-10-02 1977-11-25 Делаланд С.А. (Фирма) Способ получени производных фуро32,3- /-пиримидина
RU1391052C (ru) * 1986-08-25 1993-11-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 5-формилтиено [2,3-D]пиримидина, обладающие противогерпетической активностью
US20030236271A1 (en) * 2000-04-27 2003-12-25 Masahiko Hayakawa Fused heteroaryl derivatives
WO2006046031A1 (en) * 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
DE1959403A1 (de) * 1969-11-26 1971-06-03 Thomae Gmbh Dr K Neue 2-(5-Nitro-2-furyl)-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO62428A (fr) * 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
ZA782648B (en) * 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
US5075305A (en) * 1991-03-18 1991-12-24 Warner-Lambert Company Compound, composition and use
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
KR20030034232A (ko) * 2000-09-29 2003-05-01 닛뽕소다 가부시키가이샤 티에노피리미딘 화합물 및 그 염 및 제조방법
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
DE202005022026U1 (de) * 2004-06-03 2012-06-21 Nordson Corp. Farbwechsel für ein System zum Auftragen von Pulverbeschichtungsmaterial
EP1806347A4 (en) * 2004-10-08 2009-07-01 Astellas Pharma Inc PYRIMIDINE DERIVATIVES FUSED WITH AN AROMATIC RING
TWI498332B (zh) 2006-04-26 2015-09-01 Hoffmann La Roche 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
RU2008141356A (ru) 2006-04-26 2010-06-10 Ф. Хоффманн-Ля Рош Аг (Ch) Производные пиримидина в качестве ингибиторов фосфатидилинозитол-3-киназы (pi3k)
CN101511840A (zh) * 2006-04-26 2009-08-19 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物及其使用方法
MX2008013578A (es) * 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
GB0608820D0 (en) 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
WO2008070740A1 (en) 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2050814A1 (de) * 1970-10-16 1972-04-20 Dr. Karl Thomae Gmbh, 7950 Biberach Neue Verfahren zur Herstellung von 2-(5-Nitro-2-furyl)-thieno eckige Klammer auf 3,2-d eckige Klammer zu pyrimidinen
SU419037A3 (https=) * 1970-11-26 1974-03-05 Эберхард Войтун, Герхард Онаккер, Бертольд Нарр, Ульрих Хорх , Рудольф Кадац
SU581868A3 (ru) * 1973-10-02 1977-11-25 Делаланд С.А. (Фирма) Способ получени производных фуро32,3- /-пиримидина
RU1391052C (ru) * 1986-08-25 1993-11-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 5-формилтиено [2,3-D]пиримидина, обладающие противогерпетической активностью
US20030236271A1 (en) * 2000-04-27 2003-12-25 Masahiko Hayakawa Fused heteroaryl derivatives
WO2006046031A1 (en) * 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029601B1 (ru) * 2013-12-23 2018-04-30 Ле Лаборатуар Сервье Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их

Also Published As

Publication number Publication date
US9487533B2 (en) 2016-11-08
PE20081353A1 (es) 2008-11-12
JP5500990B2 (ja) 2014-05-21
EP2114950B1 (en) 2016-03-09
NO342697B1 (no) 2018-07-09
CN101675053A (zh) 2010-03-17
AU2007333243B2 (en) 2013-03-14
CN101675053B (zh) 2014-03-12
RU2009125916A (ru) 2011-01-20
US20080269210A1 (en) 2008-10-30
KR101507182B1 (ko) 2015-03-30
MX2009005925A (es) 2009-08-12
WO2008073785A3 (en) 2008-08-28
ZA200904531B (en) 2010-09-29
ES2571028T3 (es) 2016-05-23
BRPI0717907A2 (pt) 2013-11-05
AU2007333243A1 (en) 2008-06-19
IL199151A (en) 2017-01-31
AR064154A1 (es) 2009-03-18
JP2010512337A (ja) 2010-04-22
CA2671845A1 (en) 2008-06-19
CA2671845C (en) 2015-03-24
WO2008073785A2 (en) 2008-06-19
CL2007003523A1 (es) 2008-08-22
NO20092565L (no) 2009-09-07
KR20090106508A (ko) 2009-10-09
EP2114950A2 (en) 2009-11-11
TW200829594A (en) 2008-07-16
IL199151A0 (en) 2010-03-28

Similar Documents

Publication Publication Date Title
RU2470936C2 (ru) Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
EP2518074B1 (en) Phosphoinositide 3-kinase inhibitor compounds and methods of use
ES2399774T3 (es) Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso
US7846929B2 (en) Phosphoinositide 3-kinase inhibitor compounds and methods of use
CN101600720A (zh) 磷酸肌醇3-激酶抑制剂化合物及使用方法

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20191206